Our Moments
NOW – 2021
NOW – 2021
2026
- Launched 'MAP(Medytox Academy of Precision)', a new academic education program
- Obtained China NMPA approval for NEURAMIS® Deep Lidocaine and Volume Lidocaine
- Obtained approval for a next generation botulinum toxin NEWLUX® 200U (NUMECO)
- Obtained European MDR CE certification for NEURAMIS® Deep Lidocaine and Volume Lidocaine
- Launched LactiPLAN®, probiotics for body fat reduction
2025
- Signed Exclusive Supply Agreement for NEURAMIS® and NEWLUX® with Middle Eastern Partner AMICO Group
- Obtained MFDS Marketing Authorization for NUVIJU®, the world's first cholic acid-based injectable adipocytolytic agent for submental fat reduction
- Obtained individually recognized functional ingredient status for 'MT961', a proprietary probiotic for body fat reduction
- Conducted an environmental plogging campaign
- Launched NEURAMIS® Heart, Skin Enhancer and renewed four NEURAMIS® product lines
2024
- Signed a distribution contract with Hainan Stone Investment CO., LTD., for the export of NEURAMIS® and NEWLUX® to China
- Obtained KGMP Approval for Building E of Medytox Plant Ⅲ(Osong)
- Obtained international certifications for ISO 37301 (Compliance), ISO 37001 (Anti-Bribery), and ISO 27001 (Information Security) Management Systems
- Signed a botulinum toxin distribution agreement worth USD 73 million with Blau Farmacêutica
- Established a subsidiary in the US, Luvantas
2023
- Obtained approval for a next generation botulinum toxin NEWLUX® (NUMECO)
- Obtained international certifications for ISO 14001 (Environmental) and ISO 45001 (Occupational Health and Safety) Management Systems
- Renamed Medytox Korea to 'NUMECO'
2022
- Donated 100 million won to the Embassy of Ukraine as a relief fund
2021
- Terminated the License Agreement with Allergan Inc. (US) for new formulation of new botulinum toxin type A
- Established a Thailand local subsidiary, Medytox (Thailand) Co., Ltd.
2020 – 2011
2020 – 2011
2020
- Selected as Certified Trading Company (Ministry of Trade, Industry, and Energy)
- Launched a cosmeceutical brand, NEURADERM
2019
- Selected as 2019 Asia’s Most Trusted Company
- Obtained approval from MFDS for Potenfill, a hyaluronic acid (HA) filler product
- Launched Khan's Morning®, patented probiotics
2018
- Received $100M Export Tower Award
- Began phase 3 trials of new formulation of botulinum toxin type A in US, Canada by Allergan Inc. (US)
- Received the presidential commendation award at the 2018 Governor's Job Creation Awards (Ministry of Employment and Labor)
- Received a plaque of appreciation from the Cheongju Family-Friendly Community UCC Network (Cheongju City)
- Neuronox® and NEURAMIS®, selected as "Korea's World-class Products" in 2018 (Ministry of Trade and Industry)
- Launched Global CSR Campaign ‘Team 2022’
- Selected as 2018 the Best Job Creation Company in Korea (Ministry of Employment and Labor)
2017
- Completed Medytox Gwanggyo R&D Center construction
- Established a Thailand joint venture, MedyCeles
- Medytox headquarters relocated to the Global Business Center (GBC) (Daechi-dong, Gangnam-gu, Seoul)
2016
- Received $30M Export Tower Award
- Completed Medytox Plant III (Osong) construction, the biggest scale in Korea
- Obtained approval from MFDS for 150kDa non-animal botulinum toxin type A product, CORETOX® 100U
2015
- Received the Presidential Commendation of Technology Development Division with Special Merit (Ministry of Trade, Industry, and Energy)
- Received the USD 20 Million Export Tower Award
- Received Korea's Proud Trader Award in 2015 (Ministry of Trade, Industry, and Energy, Korea International Trade Association)
- Received Minister of Industry Commendation on the 5th Industrial Technology Protection Day (Ministry of Trade, Industry and Resources, and Korean Intellectual Property Office)
- Established a Hong Kong joint venture, Medytox Hong Kong
- Established a Japan local subsidiary, MDT International Inc.
- Established a Taiwan joint venture, Medytox Taiwan
2014
- Obtained approval from MFDS for Atière®, a hyaluronic acid (HA) filler product
- Obtained approval from MFDS for Neuramis® Lidocaine Series
- Selected as K-Brain Power (Ministry of Trade, Industry, and Energy)
- Received the Grand Prize at the 6th Korea Technology Award (Ministry of Trade, Industry, and Energy)
- Completed cGMP / EU GMP compliant Medytox Plant II (Osong) construction
2013
- Obtained approval from MFDS for Innotox® 25U, worlds’ first non-animal-derived liquid formulation botulinum toxin type A product
- Obtained approval from MFDS for Meditoxin® 150U
- Obtained approval from MFDS for Neuramis Deep®, a hyaluronic acid (HA) filler product
- Opened Medytox US Office
- Established NUMECO (domestic sales corporation)
- Signed a License Agreement with Allergan Inc. (US) formulation of new botulinum toxin type A
2012
- Completed global phase II clinical study for new formulation of botulinum toxin product (Australian Therapeutic Goods Administration, TGA)
- Meditoxin® approved for treatment of post stroke upper limb local muscle spasticity for Meditoxin®
- Designated as Innovative Pharmaceutical Company (Ministry of Health and Welfare)
- Groundbreading ceremony of cGMP compliant Medytox Plant II (Osong)
2011
- Received $10M Export Tower Award
- Received CE marking for hyaluronic acid filler Neuramis® Deep
- Obtained approval for global phase II clinical study for a new botulinum toxin product (Australian Therapeutic Goods Administration (TGA))
- Meditoxin® approved for treatment of glabellar wrinkles
- Obtained KGMP approval for Filler Department of Medytox Plant I (Ochang)
- Selected as World Advanced Technology Center (WATC) (Ministry of Knowledge Economy)
2010 – 2000
2010 – 2000
2010
- Obtained approval for global phase I clinical study for a new formulation of botulinum toxin product (Australian Therapeutic Goods Administration (TGA))
- Announced new CI (Company Identity) for Medytox Inc.
- Gained insurance coverage of indications for foot deformities due to spasticity in pediatric cerebral palsy patients with Meditoxin®
- Selected as INNO-BIZ (Innovation Business)
- Approved for treatment of foot deformity due to spasticity in pediatric cerebral palsy patients with Meditoxin®
- Obtained approval from MFDS for Meditoxin® 50U
2009
- Received $5M Export Tower Award
- Obtained approval from MFDS for Meditoxin® 200U
- Listed on KOSDAQ
2008
- Received $3M Export Tower Award
- Selected as Bio Star Enterprise (Ministry of Knowledge Economy)
2007
- Received 2007 Prime Minister Commendation by Venture Korea
- Opened Medytox Korea Seoul office
2006
- Meditoxin® selected as World-Class Product of Korea 2026 (Ministry of Commerce Industry and Energy)
- Obtained approval from MFDS for Korea’s first, world’s fourth botulinum toxin type A, Meditoxin® 100U
2004
- Obtained KGMP approval for Medytox Plant I (Ochang)
2002
- Completed Medytox Plant I (Ochang) construction
2001
- Established Microbial Toxin R&D Center at Medytox
2000
- Established Medytox Inc. (May 2nd)